Lexeo Therapeutics, Inc.
LXEO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001907108
In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 152 institutions reported holding it in 13F filings for Q3 2026, worth $310.0M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $244.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $18.2K in total
- 3
- 13F holdersQ3 2026, +15 vs. previous quarter
- 152
- 13F valueReported value at the end of Q3 2026
- $310.0M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$100.0M
- No comparable prior period
- Free cash flow, FY2025
- -$99.0M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 17.0M
- Shares sold short
- Change
- −516.1K
- −2.9% vs. previous
- Days to cover
- 12.73
- At average daily volume
Superinvestors holding LXEO, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding LXEO at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Lexeo Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 (view filing)5:00 PM ET | Nov 17 | 1 day | Tamayo Louis EdwardChief Financial Officer | SSale | −1.01K | $3.26 | −$3.28K | −1.1%91.9K after | |
| Nov 18, 2026 (view filing)5:00 PM ET | Nov 17 | 1 day | Otero Jose ManuelChief Operating Officer | SSale | −1.28K | $3.26 | −$4.19K | −0.9%137.0K after | |
| Nov 18, 2026 (view filing)5:00 PM ET | Nov 17 | 1 day | Townsend Richard NolanChief Executive Officer | SSale | −3.29K | $3.26 | −$10.7K | −0.9%373.5K after | |
| Aug 19, 2026 (view filing)5:00 PM ET | Aug 18 | 1 day | Tamayo Louis EdwardChief Financial Officer | SSale | −4.12K | $4.91 | −$20.2K | −4.2%92.9K after | |
| Aug 19, 2026 (view filing)5:00 PM ET | Aug 18 | 1 day | Townsend Richard NolanChief Executive Officer | SSale | −3.35K | $4.95 | −$16.6K | −0.9%374.5K after | |
| Aug 19, 2026 (view filing)5:00 PM ET | Aug 18 | 1 day | Otero Jose ManuelChief Operating Officer | SSale | −1.30K | $4.96 | −$6.46K | −0.9%136.2K after | |
| Jul 1, 2026 (view filing)6:49 PM ET | Jul 1 | Same day | Tamayo Louis EdwardChief Financial Officer | SSale | −4.64K | $4.49 | −$20.8K | −4.6%97.0K after | |
| Jul 1, 2026 (view filing)6:49 PM ET | Jul 1 | Same day | Otero Jose ManuelChief Operating Officer | SSale | −4.67K | $4.48 | −$20.9K | −3.3%137.5K after | |
| Jul 1, 2026 (view filing)6:48 PM ET | Jul 1 | Same day | Bhalla Narinder PalChief Medical Officer | SSale | −22.3K | $4.42 | −$98.6K | −21.3%82.2K after | |
| Jul 1, 2026 (view filing)6:47 PM ET | Jul 1 | Same day | Townsend Richard NolanChief Executive Officer | SSale | −25.9K | $4.48 | −$116.2K | −6.4%377.8K after |
Top 10 13F holders, Q3 2026
See all 152 holdersThe largest institutional positions in Lexeo Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 7,245,611 | $24.5M | 1.39% | +1,438,000+24.8% | Added |
| Suvretta Capital Management, LLC | 6,384,200 | $21.6M | 0.60% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,973,615 | $20.2M | 0.00% | +234,160+4.1% | Added |
| Ra Capital Management, L.P. | 5,000,000 | $16.9M | 0.17% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 4,824,725 | $16.3M | 0.40% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 4,583,248 | $15.7M | 0.00% | +4,486,958+4,659.8% | Added |
| Vestal Point Capital, LP | 4,320,000 | $14.6M | 0.38% | 00.0% | Unchanged |
| Citadel Advisors LLC | 4,236,938 | $14.3M | 0.01% | +338,368+8.7% | Added |
| Balyasny Asset Management LLC | 3,987,787 | $13.5M | 0.03% | +1,575,045+65.3% | Added |
| Millennium Management LLC | 3,778,541 | $12.8M | 0.01% | +944,919+33.3% | Added |
Holders of 5% or more of LXEO
See all 11 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Lexeo Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Balyasny Asset Management LLC | 13G/A | 9.99%8.20M shares | 0.00 ppfrom 9.99% | Aug 14, 20256 filings | Nov 16, 2026 | SEC |
| Affinity Asset Advisors, LLC | 13G/A | 9.80%8.11M shares | +1.40 ppfrom 8.40% | Jun 4, 20254 filings | Nov 13, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G | 7.70%5.67M shares | New | Apr 13, 20261 filing | Apr 13, 2026 | SEC |
| Citadel Advisors LLC | 13G/A | 7.40%5.50M shares | −2.20 ppfrom 9.60% | Nov 17, 20234 filings | Feb 17, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 7.20%5.94M shares | −2.79 ppfrom 9.99% | Feb 14, 20249 filings | Nov 16, 2026 | SEC |